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Nuclear IKKa regulates gene transcription by phos-
phorylating specific substrates and has been linked
to cancer progression and metastasis. However, the
mechanistic connection between tumorigenesis and
IKKa activity remains poorly understood. We have
now analyzed 288 human colorectal cancer samples
and found a significant association between the
presence of nuclear IKK and malignancy. Impor-
tantly, the nucleus of tumor cells contains an active
IKKa isoform with a predicted molecular weight of
45 kDa (p45-IKKa) that includes the kinase domain
but lacks several regulatory regions. Active nuclear
p45-IKKa forms a complex with nonactive IKKa
and NEMO that mediates phosphorylation of SMRT
and histone H3. Proteolytic cleavage of FL-IKKa
into p45-IKKa is required for preventing the
apoptosis of CRC cells in vitro and sustaining tumor
growth in vivo. Our findings identify a potentially
druggable target for treating patients with advance
refractory CRC.
INTRODUCTION
NF-kB is a transcription factor that regulates innate and acquired
immune responses, inflammation, and cancer (Hayden and
Ghosh, 2004; Hayden et al., 2006; Schulze-Luehrmann and
Ghosh, 2006). In the absence of stimulation, NF-kB dimers
(such as p65/p50) are primarily cytoplasmic and bound to the
inhibitor of kB (IkB). Induction of canonical NF-kB pathway by
specific stimuli, such as tumor necrosis factor (TNF)-a, bacterial840 Cell Reports 2, 840–854, October 25, 2012 ª2012 The Authorsand viral products, or DNA damage, leads to the activation of the
IKK (IkB kinase) complex that phosphorylates IkB inducing its
degradation and nuclear translocation of the NF-kB factor. The
IKK complex is composed of two catalytic subunits, IKKa/IKK1
and IKKb/IKK2, and the regulatory IKKg/NEMO (for NF-kB
Essential Modifier). Molecular weight of IKKa and IKKb is 85
and 87 kDa, respectively, and they share 50% of amino acid
identity and 70% of structural similarity. IKKa and b contain an
amino-terminal kinase domain, a leucine zipper (LZ) region
involved in protein dimerization and a helix-loop-helix (HLH)
(DiDonato et al., 1997; Zandi et al., 1997). Recently, LZ and
HLH regions of IKK have been redefined based on structural
data of IKKb (Xu et al., 2011). It is established that IKKb and
NEMO are essential mediators of IkB degradation and canonical
NF-kB activation. Conversely, activation of IKKa by LTb, CD40,
or BAFF induces processing of p100 into p52. Then, p52/RelB
dimers translocate to the nucleus and activate specific gene
transcription. This signaling pathway, known as alternative
NF-kB, is required for secondary lymphoid organogenesis
(Senftleben et al., 2001).
In addition to its cytoplasmic functions, nuclear roles for
IKKa have recently been identified such as binding to the
chromatin of specific promoter regions to phosphorylate serine
10 of histone H3, which affects chromatin condensation and
facilitates transcriptional activation of NF-kB-dependent
and -independent genes (Anest et al., 2003, 2004; Park et al.,
2005; Yamamoto et al., 2003). Nuclear IKKa also regulates
cell-cycle progression through phosphorylation of the AuroraB
kinase (Prajapati et al., 2006) and derepression of 14-3-3s (Zhu
et al., 2007b). In cancer cells, chromatin-bound IKKa activates
the metastasis-related gene,maspin, through epigenetic modifi-
cations (Luo et al., 2007) and associates with other factors such
asNotch to regulate specific transcription (Hao et al., 2010; Song
et al., 2008; Vilimas et al., 2007). Moreover, IKKa activates
cIAP2 and IL-8 transcription through phosphorylation of the
nuclear corepressor SMRT at serine 2410, which induces its
cytoplasmic export and degradation (Hoberg et al., 2004). We
previously demonstrated that colorectal cancer (CRC) cells
contain nuclear IKKa, which phosphorylates SMRT and N-CoR
leading to the activation of Notch-target genes hes1 and herp2
(Ferna´ndez-Majada et al., 2007a, 2007b). This is important since
Notch activity is required for CRC progression (Fre et al., 2005;
van Es et al., 2005). Interestingly, inhibition of IKK activity
reverted Notch-target gene expression and reduced tumor
xenografts growth in nude mice (Ferna´ndez-Majada et al.,
2007a, 2007b). However, IKK activity is essential for multiple
physiological functions, including regulation of immune
response, differentiation of lymph nodes, mammary gland, and
skin, and maintenance of liver and gut homeostasis (Luedde
et al., 2007; Nenci et al., 2007; Pasparakis et al., 2002), and
consequently, cannot be inhibited without producing severe
undesirable effects (Chen et al., 2003; Greten et al., 2007; Maeda
et al., 2005).
In this work, we study the traits that distinguish CRC-related
IKK functions from those associated with physiological NF-kB,
which has critical implications for further identification of thera-
peutic druggable targets. We show that nuclear localization of
active IKKa is a common event associated with advanced
human CRC, and identify a truncated form of IKKa (referred to
as p45-IKKa) that represents the majority of active IKK in this
cellular compartment. Truncated IKKa is generated by cathepsin
activity, which is increased in CRC. At the biochemical level,
active p45-IKKa is in a nuclear complex with NEMO, which
specifically phosphorylates SMRT leading to specific gene
transcription. Knocking down IKKa prevents growth of CRC
cells both in vitro and in vivo, and this effect is rescued by small
hairpin RNA (shRNA)-resistant IKKa but not by a cleavage-
defective mutant. Together, our results indicate the possibility
to target p45-IKKa generation or activation as a strategy for
CRC treatment.
RESULTS
CRC Cells Contain a Nuclear Form of IKKa of 45 kDa
Activation of nuclear IKKa has been previously associated with
human CRC and prostate metastasis in mouse (Ferna´ndez-
Majada et al., 2007a; Luo et al., 2007). We here analyze a total
of 288 samples (147 adenomas and 141 carcinomas) and the
corresponding paired distal normal mucosa from 98 patients
and found that more than 60% of the adenomas and 85% of
the carcinomas show high P-IKK staining (considering ++
plus +++ intensities) compared with adjacent normal tissues
(19% positive), as detected by immunohistochemistry (IHC)
with two antibodies recognizing phosphorylated serines 180/
181 of IKKa and b, respectively (a-P-IKK, Cell Signaling no.
2681 and Santa Cruz sc-23470) (Figures 1A and 1B). Most of
the positive samples showed strong punctuate cytoplasmic
staining; in addition 30% of adenomas and 40% of carcinomas
contain detectable levels of nuclear P-IKK (Figures 1A, 1C, and
1D). Confocal microscopy confirmed the presence of nuclear
P-IKK in 11 out of 12 randomly selected samples identified
as nuclear positive in the general screening, and its absence inC12 out of 12 negative samples (96% correspondence). A more
detailed analysis revealed that, even in the positive tumors,
most of P-IKK was localized in cytoplasmic vesicles, being the
nuclear staining restricted to discrete dots (Figure S1A; data
not shown). To further investigate the nature of tumor-associated
nuclear IKK, we performed subcellular fractionation followed
by western blot analysis of fresh CRC samples and normal
adjacent mucosa (N) from 4 different patients and 2 human
carcinomas grown as xenograft in nude mice (CRCX). We found
that most of the active P-IKK corresponding to the expected
size of 85–87 kDa was localized in the cytoplasm of tumor and
normal cells. Unexpectedly, the same antibody recognized
a double band of around 45 kDa that was highly enriched in
both the cytoplasmic and nuclear fractions of carcinoma cells
(from now on p45-IKK) (Figure 1E). Active p45-IKK was also
detected in human CRC cell lines using two different a-P-IKK
antibodies (Cell Signaling no. 2681 and no. 2697) (Figure 1F)
and from extracts obtained in the presence of specific protease
inhibitors (Figure S1B, lanes 2 and 3) or directly boiled in 1%SDS
sample buffer and electrophoresed without further manipulation
(Figure S1B, lane 4). a-IKKa antibody, but not a-IKKb, recog-
nized bands compatible with p45-IKK in all tested CRC cells
(Figure 1F) and human CRC samples (Figure 1E), suggesting
that p45-IKK was an isoform of IKKa. Of note, that nonphos-
phorylated p45-IKK was also detected in the cytoplasm of
nontransformed cells (Figure 1E). To further demonstrate that
p45-IKK was a product of IKKa, we performed knockdown
experiments in HCT116 and Ls174T cells, followed by western
blot analysis. We found that different shRNA targeting IKKa
reduced both the 85 kDa and the 45 kDa bands detected with
a-IKKa antibody from total (Figure 1G) and nuclear extracts
(Figure S1C). In contrast, IKKb levels were not affected, demon-
strating the specificity of the shRNA, although we observed
a reduction of NEMO levels (Figures 1G and S1D) that did not
affect canonical NF-kB activity as detected by IkBa phosphory-
lation after TNF-a treatment (Figure S1D). Besides, we detected
low levels of p45-IKKa in mouse embryonic fibroblasts (MEFs)
that were absent from IKKa knockout (KO) MEFs (Figure S1E)
supporting the IKKa nature of p45. Importantly, antibodies
recognizing phosphorylated IKK failed to detect this band (data
not shown), as in normal human samples (Figure 1D), suggesting
that p45-IKKa is inactive in nontransformed cells. Further
demonstrating that p45-IKKa is phosphorylated in CRC, treat-
ment of HCT116 nuclear extracts with calf intestinal alkaline
phosphatase (CIAP) abrogated detection of p45-IKK by a-P-
IKK (Figure S1F). These results indicate the existence of an
IKKa species with an apparent size of 45 kDa that represents
the majority of active IKK in the nucleus of CRC cells. Con-
versely, nontransformed cells contain nonphosphorylated
p45-IKKa, which is localized in the cytoplasm.
Generation of the Nuclear p45-IKKa Form Present
in CRC Cells
We tested the possibility that high levels of p45-IKKa found in
CRC cells were due to mutations in the IKKa sequence that
translate into a truncated protein. Because of its inferred molec-
ular size, we focused on studying the region involving exons
13–15 of IKKa, which was found to be mutated in squamousell Reports 2, 840–854, October 25, 2012 ª2012 The Authors 841
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Figure 1. CRC Cells Express a Truncated and Active Form of IKKa in the Nucleus
(A) IHC with a-P-IKKa/bs from normal, adenoma and carcinoma samples (4003) from a human colon tissue microarray including 288 tumor samples.
(B) Normal mucosa, adenoma, and CRC samples were classified based on intensity of a-P-IKKa/b staining.
(C) Samples were classified depending on the presence or absence of nuclear a-P-IKKa/b staining.
(D) Percentage of positive nuclei in samples with P-IKK staining.
(E) Western blot analysis of cytoplasmic and nuclear extracts from human CRC samples and their normal adjacent tissue and two human CRC samples grown as
xenografts in nude mice.
(F) Western blot analysis of cytoplasmic and nuclear extracts from different CRC cell lines (HCT116, SW480, Ls174T, HT-29) and nontransformed cell line HS27.
(G) Western blot analysis of total cell extracts from HCT116 cells transduced with shRNA against IKKa or with a scrambled shRNA. IKKb levels are shown to
test isoform specificity.
In (B) and (C), Fisher’s exact test was used to determine p values. In (E)–(G), tubulin and lamin B were used as fractionation and loading controls. C, cytoplasmic;
N, nuclear. See also Figure S1.cell carcinomas (Liu et al., 2006). First, we performed single-
strand conformational polymorphism (SSCP) analysis of this
region, amplified using intronic primers from genomic DNA842 Cell Reports 2, 840–854, October 25, 2012 ª2012 The Authorscorresponding to 161 human CRC samples (5 stage I, 52 stage
II, 83 stage III, and 21 stage IV). In this screening, we did not
detect any alteration beyond a single nucleotide change in an
intronic region of sample 515T (Figure S2A; data not shown).
By direct sequencing, we confirmed the absence of mutation
in this region using genomic DNA from HCT116, HT-29, and
SW480 cells, as well as 16 human CRC samples. Interestingly,
analysis of the cDNA identified a deletion of exon 14 in one of
the samples that led to a frameshift that generates a premature
STOP codon at position 520 (data not shown). Together, these
data indicate that mutation of the IKKa gene is not the main
mechanism contributing to p45-IKKa generation.
Next, we investigated whether p45-IKKa was produced by
FL-IKKa processing. With this objective, we transduced
HEK293T, HCT116, and HT-29 cells with a retroviral vector codi-
fying for FL-IKKa fused to the myc epitope at the N-terminal end
(myc-IKKa). Western blot analysis of the lysates demonstrated
the presence of the expected 85 kDa IKKa protein, in addition
to a 45 kDa that was recognized with the a-myc antibody
(Figure 2A). In HEK293T cells, myc-IKKa generated a pattern of
bands that was identical to the endogenous IKKa fromCRC cells
(Figure S2B), although p45 was more prominent in CRC cells.
Identity of the 45 kDa band was further established by precipita-
tion of HA-IKKa with the a-HA antibody followed by detection
with specific a-IKKa antibody generated against its N-terminal
end (Figure 2B) and by conventional mass spectrometry analysis
of the tryptic peptides (data not shown). Generation of p45-IKKa
from HA-IKKa was not modified by mutation of serines 176
and 180 to alanine (S176/180A) or glutamic acid (S176/180E),
indicating its activation status was not necessarily linked with
cleavage (Figure S2C). These results indicate that FL-IKKa
generates p45-IKKa, which comprises the N-terminal kinase
and the ubiquitin-like domain (ULD) but lacks the regulatory
scafold/dimerization domain (SDD) (Figure 2C). Since IKK
exhibits a conformation that involves the physical interaction of
SDD with the ULD and kinase domains (Xu et al., 2011), we pre-
dicted that p45-IKKa might differentially expose the regions
close to the cleavage site compared with FL-IKKa. Based on
this, and to further study the distribution and prevalence of
p45-IKKa in human samples, we generated monoclonal anti-
bodies against peptide amino acids (aa) 241–424 of human
IKKa and tested for their capacity to precipitate p45-IKKa from
nondenatured CRC cell lysates. Among these antibodies, we
obtained the clone 881H3 that preferentially binds p45-IKKa
from tumor cell lysates compared with the full-length (FL) nonde-
natured form (Figure S2D) and generated a specific staining
pattern in WT MEF that was not detected in IKKa KO cells (Fig-
ure S2E). In CRC cells, staining with the 881H3 antibody was
found in the nucleus and cytoplasm and was lost in cells treated
with shRNA against IKKa (Figure S2F). Thus, we selected 881H3
to study the distribution of p45-IKKa by IHC in human samples.
In CRC samples, 881H3 generated a specific staining pattern
that resembled active P-IKKa including cytoplasmic vesicles
and discrete nuclear dots (Figures 2D and 2E). By double IHC
and confocal microscopy analysis, we detected a substantial
colocalization of p45-IKKa with P-IKK in CRC (Figure 2F). As
a control, staining with 881H3 in CRC was lost after incubation
with the blocking peptide (Figure S2G). Positive staining for
p45-IKKa was also detected in normal colonic mucosas previ-
ously categorized as negative for P-IKK, mainly restricted to
the proliferative basal regions (Figure S2H). By crossing ourCdata from active IKK (P-IKK) and p45-IKKa expression, we found
that detection of p45-IKKa levels was independent of P-IKK
status in the normal mucosa but it was associated in the CRC
group of samples (Figures 2D and 2G). A more detailed study
of the correlation between p45-IKKa and P-IKK staining demon-
strated that p45-IKKa levels significantly and positively corre-
lated with P-IKK reactivity in CRC samples (Figure 2H).
Cathepsin-Mediated Processing Generates
p45-IKKa In Vitro
To identify putative proteases that mediate IKKa processing, we
created a Python script and queried for candidates using the
information in the MEROPS peptidase database (Rawlings
et al., 2010). This search was performed using the region
including exons 13–14 as a target sequence (aa 300–450). We
identified three putative cleavage sites for caspase 3/6/7,
cathepsin B/L and cathepsin K that could account for the
generation of p45-IKKa (Figure 3A). To test whether these sites
were functional, we designed an expression vector containing
themyc tag fused to the aa 300–450 IKKa fragment that includes
all three sites. We found that this IKKa fragment expressed in
HEK293T cells generated a 25 kDa band when incubated at
acid pH (optimal for cathepsin activity), which was further
increased after incubation with nuclear extracts from Ls174T
CRC cells (Figure 3B). Treatment with z-FA-FMK, a specific
inhibitor of cathepsin B and L (Sillence and Allan, 1997) but not
with the caspase inhibitor z-VAD (not shown), significantly
reduced IKKa processing in these experiments (Figure 3C).
Next, we generated point mutants of the FL-IKKa construct
to disrupt each of the identified protease recognition sites indi-
vidually and in combination. As shown in Figure 2A, we found
that myc-IKKa expressed in HCT116 cells was efficiently pro-
cessed into p45-IKKa; however, single mutations in cathepsin
or caspase sites, and the triple mutation of all three protease
recognition sites (3M) reduced IKKa cleavage (from 45% in the
WT to 9%–10%, 12%, and 6% in the mutants, respectively).
Similarly, the IKKa-3M mutant failed to be processed in non-
transformed cells (Figure 3D). These results suggest that all
three sites might contribute to some extent to p45-IKKa gene-
ration. To further define the cleavage site for p45-IKKa gene-
ration, we performed a more detailed analysis of the mass
spectrometry data obtained from the precipitated HA-p45-
IKKa fragment. In these experiments we failed to detect most
of the central region of the IKKa protein (were cleavage is pre-
dicted to occur) but we identified a single peak (extracted ion
chromatogram) compatible with the expected end-terminal
sequence generated from Cathepsin B/L cleaved IKKa protein
after trypsin digestion (peptide TVYEGPFAS). In contrast, we
did not detect any tryptic peptide with the characteristics
of a Caspase- or Cathepsin K-processed IKKa fragment
(not shown). Together, these results indicate that p45-IKKa is
generated by specific protease activity, most likely through
cathepsins.
p45-IKKa Is Generated by Cathepsin-Dependent
Processing In Vivo
To investigate the putative involvement of cathepsins in gener-
ating p45-IKKa in vivo, we ectopically expressed FL-IKKa aloneell Reports 2, 840–854, October 25, 2012 ª2012 The Authors 843
Figure 2. p45-IKKa Is Generated by Proteolytic Processing of the Full-Length Form and Corresponds to the Amino-Terminal Half of the
Kinase
(A) Cell lines were transduced with a retroviral vector expressing myc-IKKa. Total lysates were analyzed by western blot using an antibody against the myc
epitope (9E10 clone).
(B) HEK293T cells were transfected with HA-IKKa, HA-IKKb, and HA-IkBa, and, 48 hr after transfection, cell lysates were immunoprecipitated with a-HA antibody
and the precipitates were analyzed by western blot with a-HA and a-IKKa antibodies. One of three independent experiments performed is shown.
(C) Schematic representation of FL-IKKa that contains the kinase domain, the ubiquitin-like domain (ULD), an the elongated a-helical scaffold/dimerization
domain (SDD), including the regions previously characterized as LZ and HLH domains, and the NEMO-binding domain (NBD). Predicted truncated p45-IKKa
includes the kinase domain but lacks the SDD and the NBD regions.
(D) Serial sections of human intestinal mucosa, adenoma, and carcinoma samples were stained with a-P-IKK and anti-p45-IKKa (881H3) antibodies and visu-
alized by confocal microscopy.
(E) Detail of nuclear and cytoplasmic p45-IKKa staining in one CRC sample.
(F) Colocalization of p45-IKKa with P-IKK staining in three different CRCs.
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Figure 3. p45-IKKa Is Generated In Vitro by Cathepsin-Mediated Processing
(A) Bioinformatic analysis of the region including AA 300–450 of IKKa revealed the presence of putative protease cleavage sites for caspase 3/6/7, cathepsin B/L,
and cathepsin K.
(B) HEK293T cells expressing the MT-IKKa 300–450 construct were lysed in PBS plus protease inhibitor cocktail (pH 8.0) or 10 mM HEPES (pH 5.5). Cell lysates
were incubated with two volumes of 100 mg/ml BSA or Ls174T lysates for 2 hr at 4C and western blot analysis was performed.
(C) HEK293T cells expressing MT-IKKa 300–450 WT were lysed in pH 8.0 plus protease inhibitor cocktail buffer, pH 8.0 buffer or pH 5.5 buffer with or without
20 mM z-FA-FMK as indicated, in the presence of LS174T lysates, incubated for 2 hr at 4C and analyzed by western blot.
(D) HCT116 cells (left) or IKKa KOMEFs (right) expressingmyc-IKKaWT or the indicatedmutants were lysed in buffer containing protease inhibitors and analyzed
bywestern blot. All the experimentswere repeated aminimumof three timeswith comparable results. Percentage of cleaved IKKa relative to the FL or the aa 300–
450 fragment (determined by densitometry from a representative experiment) is shown at the bottom of each lane.or together with cathepsin B, L, K or caspase 3 in HEK293T cells.
We found that expression of either cathepsin homolog increased
generation of p45-IKKa compared with cells transfected with
control vector (Figure 4A) or caspase 3 (Figure S3A). In agree-
ment with the possibility that cathepsins mediate IKKa cleavage
inCRC cells, we found increased levels of cathepsin L (Figure 4B)
and B (data not shown) in both nuclear and cytoplasmic lysates,
associated with high cathepsin B/L activity (Figure 4C) in all
tested CRC cell lines compared with nontransformed HS27
cells. However, cathepsin B/L activity does not strictly correlate
with levels of active p45-IKKa in each individual cell line, indi-
cating that cathepsin-mediated processing is a tightly regulated
process. Most important, abrogation of cathepsin B/L activity by
the pharmacological inhibitor z-FA-FMK mostly abolished
formation of endogenous nuclear p45-IKKa in CRC cells (Figures
4D and S3B). By IF followed by confocal microscopy analysis,
we detected high levels of cathepsin B and L in human primary(G) A group of 183 human colon tumors and 55 normal mucosas, previously chara
represent the distribution of p45-IKKa staining in samples categorized as negativ
P-IKK and p45-IKK expression was distributed randomly in the normal mucosa (X
(H) Spearman Rho test demonstrated a linear positive correlation between P-IKK
See also Figure S2.
CCRC tumors that colocalized with P-IKK in specific ring-shaped
cytoplasmic vesicles reminiscent of lysosomal or endosomal
structures (Figures 4E and S3C). In these vesicles, P-IKK ap-
peared restricted to the membrane rings where it costains with
the specific a-IKKa antibody (Figure S3D), when compared
with the more central localization of cathepsins B or L. Different
controls for cross-reaction of antibodies or cross-contamination
of fluorochromes were performed (Figure S3E). Further charac-
terization of these structures demonstrated that they contained
RAB5, a small GTPase protein involved in trafficking of early
endosomes (Poteryaev et al., 2010) (Figure 4F), and we found
colocalization between P-IKK and some vesicles positive for
the late endosomal marker RAB7 (Figure 4G). In contrast,
P-IKK detection absolutely diverged from staining with the
autophagosomal marker LC3 (Figure S3F) and the lysosomal
marker LAMP1 (Figure S3G), excluding the possibility that in
cancer cells active p45-IKKa is part of a degradation product.cterized for P-IKK, were analyzed by IHC for the presence of p45-IKKa. Tables
e or positive (+, ++, and +++) for P-IKK. Statistical analysis demonstrated that
-square test, p = 0.07) but strongly associated in the CRC samples (p = 0.0001).
and p45-IKK levels, which reached statistical significance (p = 0.01).
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Figure 4. Cathepsin-B and L Promote the Formation of p45-IKKa In Vivo
(A) HEK293T cells expressing MT-IKKa were cotransfected with control vector, MT-cathepsin B, MT-cathepsin L, or MT-cathepsin K. Forty-eight hours after
transfection, cell lysates were obtained and analyzed by western blot to determine the levels of p45-IKKa.
(B) Western blot analysis of nuclear and cytoplasmic extracts to determine Cathepsin L levels from the indicated cell lines.
(C) Cathepsin activity from the indicated CRC cell lines was determined compared with the nontransformed HS27 cells.
(D) HCT116 cell cultures were incubated for 16 hr with or without z-FA-FMK (20 mM). Cytoplasmic and nuclear cell extracts were obtained and analyzed by
western blot. In (B) and (D), a-Lamin B and a-tubulin were used as fractionation and loading controls.
(E) Confocal images of double staining for P-IKK and cathepsin B in CRC samples.
(F and G) Confocal images of double staining for P-IKK and the endosomal markers RAB5 (F) and RAB7 (G). Representative images were selected to illustrate
the degree of colocalization between different proteins in CRC.
Scale bars, 10 mm. All experiments were performed in triplicates with comparable results. See also Figure S3.
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Of note, in these samples cathepsin B was only partially distrib-
uted in the lysosomal particles (Figure S3H).
Together, these results indicate that cathepsin activity is
mainly responsible for generating p45-IKKa in CRC cells and
suggest that the interaction between IKKa and cathepsins takes
place in specific endosomal vesicles. Sorting of IKKa into these
vesicles might contribute to regulate IKKa processing.
Truncated IKKa Displays Specific Biochemical
Properties
To study the biochemical characteristics of p45-IKKa, we per-
formed gel filtration experiments in Superdex S200 columns
from HCT116 (Figure 5A) and SW480 nuclear extracts (Fig-
ure S4A) and determined the distribution of active IKKa in the
different fractions. We found that active/phosphorylated p45-
IKKa coeluted with the nonactive FL-IKKa and NEMO in the
high molecular weight (HMW) fractions (19–25) (larger than
210 kDa), whereas FL-active P-IKKa was recovered in low
molecular weight (LMW) fractions 38–45, likely corresponding
to monomeric IKKa (Figures 5A and S4A). Further suggesting
that p45-IKKa was in a HMW complex with nonactive FL-IKKa
and NEMO, p45-IKKa expressed in IKKa KO MEFs eluted in
intermediate molecular weight fractions 26–36 (Figure 5B, left
panels) and partially shifted to HMW fractions 19–24 when
FL-IKKa was reintroduced, coeluting with exogenous IKKa and
NEMO (Figure 5B, right panels). Existence of this complex was
confirmed by precipitation of endogenous NEMO from fraction-
ated nuclear HCT116 extracts (fractions 20–25) (Figure 5C) and
total cell lysates (Figure S4B) and detection of both p45 and FL-
IKKa in the precipitates. Different amounts of NEMO, FL-IKKa,
and p45-IKKa in the precipitates from the fractions suggest the
existence of specific complexes with diverse stoichiometries.
To study whether IKKb participates in this complex, we precipi-
tated myc-p45-IKKa expressed in HEK293T cells together with
HA-IKKa or HA-IKKb. We found that HA-IKKa but not HA-IKKb
associated with p45-IKKa in these conditions (Figure 5D).
Nuclear IKKa has been shown to be associated with the
chromatin through histone H3 (Zhu et al., 2007a). By pull-down
assays, we found that FL-IKKa but not p45-IKKa alone associ-
ates with histone H3 (Figure 5E); however, p45-IKKa can bind
histone H3 in the presence of FL-IKKa (Figure 5E). In agreement
with these results, we found that IKKa associates with histone
H3 through itsC-terminal region (FigureS4C). Importantly, ectop-
ically expressed p45-IKKa localized essentially in the cytoplasm
(although it retains the NLS sequence, see Figure 2C) in the
absence of endogenous IKKa, and was redistributed into the
nuclear and chromatin compartments in the presence of ectopic
FL-IKKa, as shown by western blot from IKKa-deficient MEFs
(Figure 5F). However, treatment of these cells with the nuclear
export inhibitor Leptomycin B resulted in the accumulation of
both FL-IKKa and p45-IKKa in the nucleus (Figure S4D), indi-
cating thatNLS is functional in p45-IKKabut its chromatinbinding
and nuclear retention require the participation of FL-IKKa.
p45-IKKa Promotes Phosphorylation of Specific
Substrates Both In Vitro and Vivo
We have previously shown that SMRT and N-CoR corepressors
are substrates for IKKa kinase in CRC cells (Ferna´ndez-MajadaCet al., 2007a, 2007b). To identify the nuclear fraction that
contains this kinase activity, we performed immunoprecipita-
tions of Superdex S200 fractions 19–25 (HMW) and 38–45
(LMW) from HCT116 nuclear extracts with either a-IKKa or
a-P-IKK antibodies and assayed the capacity of the precipitates
to phosphorylate glutathione S-transferase (GST)-N-CoR or
GST-SMRT fusion proteins. Precipitates obtained from the
HMW fractions (19–25) containing active p45-IKKa, but not
precipitates from fractions 38–45 (LMW) including active FL-
IKKa (Figure 6A), phosphorylated both N-CoR (Figure 6B) and
SMRT (Figure S5A) in vitro.
To further test whether p45-IKKa was involved in phos-
phorylating nuclear substrates in vivo, we transfected HA-FL-
IKKa, truncated active MT-p45-IKKa or both constructs in IKKa
KO MEFs and measured their effect on different substrates by
western blot analysis. In agreement with the in vitro data, active
p45-IKKa induced SMRT phosphorylation in serine 2410 and
this effect was enhanced by FL-IKKa. In addition, combination
of active p45-IKKa and FL-IKKa induced phosphorylation of
histone H3 (Figure 6C). These results indicate that p45-IKKa
is required for specific nuclear IKKa kinase activities, although
p45-IKKa by itself was unable to associate (Figure S5B) or
phosphorylate SMRT or NCoR in vitro (not shown). We also
measured the transcriptional effects of reintroducing FL- or
p45-IKKa in IKKa KO cells. As shown in Figure 6D, ectopic
expression of FL-IKKa induced the activation of several genes
known to be repressed by SMRT such as hes1, herp2, and
hes5. This effect was potentiated by p45-IKKa coexpression
whereas p45-IKKa alone did not have any transcriptional
effect.
Next, we investigated whether phosphorylation of nuclear
IKKa targets and transcription of SMRT-repressed genes in
CRC cells depends on p45-IKKa. To do this, we transduced
HCT116 or HT-29 cells with retroviral vectors containing an
IRES-GFP and codifying for WT IKKa, the IKKa 3M mutant
alone or 3M together with p45-IKKa. Next, we sorted the
GFP positive cells and knocked down endogenous IKKa
using shRNA that targets its 30 untranslated region (UTR)
(shRNAno. 4, Figures 1G and S1C), which does not affect the
IKK constructs. Efficiency of endogenous IKKa depletion and
expression of the different IKKa constructs was confirmed by
western blot of sorted cells (Figure 6E). We found that WT
IKKa, but not the IKKa-3M mutant, restored or even increased
phosphorylation of SMRT and histone H3 in IKKa knocked
down CRC cells. Similar effects were observed when p45-
IKKa was coexpressed with noncleavable IKKa (Figure 6E). In
contrast, IKKa-3M efficiently binds to IKKb (Figure S5C),
induces IkBa phosphorylation (Figure 6F) and was activated
by the IKK kinase TAK1 (Figure 6G). Most importantly,
changes in SMRT phosphorylation induced by IKKa reconstitu-
tion correlated with changes in the transcriptional activity of
specific SMRT targets, including the antiapoptotic gene
cIAP2 (Figure 6H).
Truncated P-IKKa Is Required for Preventing Apoptosis
and Supporting the Growth of CRC Cells
Finally, we measured the contribution of IKKa and p45-IKKa
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Figure 5. P45-IKKa Associates with Nuclear NEMO in CRC Cells
(A) Western blot analysis of cytoplasmic and nuclear extracts from HCT116 cells using the indicated antibodies (left). HCT116 nuclear extracts (100 ml) were
loaded on a Superdex200 column. One drop (40 ml approximately) per fraction was collected and analyzed by western blot with the indicated antibodies (right).
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(C) HCT116 nuclear extracts were fractionated in Superdex200 column and the indicated fractions were precipitated with the a-NEMO antibody. Western blot
analysis demonstrated the presence of endogenous FL-KKa (85 kDa) and p45-IKKa in the precipitates. The asterisk denoted a nonspecific band in the western
blot for NEMO.
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knocking down IKKa significantly inhibits the growing capacity of
all tested CRC cell lines (Figure 7A). Using the same strategy as
before (transducing WT IKKa or the 3M mutant or the IKKa
mutant plus p45-IKKa, followed by endogenous IKKa knock-
down), we tested whether p45-IKKa was required to revert
IKKa depletion in CRC cells. We found that the effects of IKKa
knockdown in CRC cell growth were specifically rescued by
WT IKKa or by the IKKa 3M mutant plus p45-IKKa but not by
IKKa 3M alone (Figure 7B). Flow cytometry analysis demon-
strated that only IKKa or 3M plus p45-IKKa protected CRC cells
from apoptosis, as measured by annexin V binding (Figure 7C)
and induced a slight, but significant, increase in cell proliferation
(Figure 7D). Prosurvival effects of p45-IKKa can be explained,
at least in part, by regulation of CIAP2 (Deveraux et al., 1998).
We next determined the capacity of HCT116 and HT-29 cells
depleted from endogenous IKKa and reconstituted with WT or
the noncleavable IKKa mutant to grow as tumor xenografts in
nude mice. CRC cells expressing WT IKKa generated signifi-
cantly larger tumors than cells expressing the IKKa mutant
(Figures 7E–7G and S6), indicating the pathological relevance
of p45-IKKa.
In summary, we have identified a cathepsin-dependent
mechanism that generates truncated IKKa, which is found in
the nucleus of tumor cells in its active form, where it is respon-
sible for specific kinase activities that directly impinge on cancer
cell growth both in vitro and in vivo.
DISCUSSION
Our results indicate that human CRC tumors display constitutive
nuclear IKKa phosphorylation, associated with increased tumor
grade. In tumor cells, we found that IKKa is proteolytically
processed into a 45 kDa fragment, in a cathepsin-dependent
manner. Moreover, p45-IKKa and P-IKK levels showed a sig-
nificant correlation in CRC samples. At the functional level, we
found that nuclear active p45-IKKa coelutes and interacts with
nonphosphorylated FL-IKKa and NEMO and is capable of phos-
phorylating SMRT and N-CoR corepressors and histone H3.
Cleavage of IKKa into p45-IKKa is required for tumor growth
in vitro and in vivo, although we detected some p45-IKKa and
P-IKK staining in few normal samples mainly restricted to
the proliferative compartment. The physiological significance
of p45-IKKa and the mechanisms regulating its generation,
activation, and nuclear translocation are currently being
investigated.
Although IKKa is mostly found in the cytoplasm associated
with IKKb and NEMO, we here demonstrate that truncated
p45-IKKa translocates to the nuclear compartment in CRC
cells where it interacts with FL-IKKa and NEMO. Which are the(D) HEK293T cells were transfected with HA-IKKa or HA-IKKb and MT-p45-IKKa.
a-HA. Western blot analysis showed that MT-p45-IKKa precipitates with HA-IKK
(E) Pull-down assay with GST-H3 and cell lysates from HEK293T cells transfected
presence of IKKa or p45-IKKa in the precipitates was determined by western blot.
The asterisk indicates a nonspecific band corresponding to GST-H3 that was de
(F) IKKa-deficient MEFs were transfected with control vector, HA-IKKa, MT-p45
obtained and analyzed by western blot with a-IKKa antibody. Levels of tubulin, l
All experiments were repeated at least three times with comparable results. See
Cmechanisms regulating formation of this IKK complex remain
unknown, but they might include availability of IKK components
(i.e., low amounts of nuclear IKKb compared with nuclear
IKKa and intermediate levels of NEMO), posttranslational modi-
fications of specific elements and the participation of adaptor
proteins.
On the other hand, it is known that IKKa phosphorylates
specific nuclear targets such as histone H3 and nuclear core-
pressors (Anest et al., 2003; Hoberg et al., 2004; Yamamoto
et al., 2003). Here, we show that p45-IKKa is required for
SMRT and histone H3 phosphorylation. By analysis of the elution
fractions from Superdex S200 columns, we detected that all the
FL-P-IKKa eluted in a LMW fraction compatible with monomeric
IKK, which is unable to phosphorylate SMRT. Which are the
substrates of nuclear FL-P-IKK kinase remains to be elucidated.
On the other hand, FL-IKKa is required for chromatin binding
of p45-IKKa association with SMRT and phosphorylation of
SMRT and histone H3 by p45-IKKa, although it retains the kinase
domain and NLS sequences. In this sense, it has been recently
demonstrated the importance of the SDD domain of IKKb (that
is conserved in IKKa) not only for substrate recognition but
also for kinase activation (Xu et al., 2011). We propose that
p45-IKKa uses the SDD and NBD domains from FL-IKKa to
achieve their functions.
Mechanisms that lead to the formation of p45-IKKamay not be
unique and are likely context dependent. Examples include
frameshift mutations generating premature STOP codons that
are present in squamous cell carcinoma (Liu et al., 2006) and
splicing variants that codify for proteins lacking the SDD as it
was found in T-lymphocytes and in the brain (McKenzie et al.,
2000). However, we did not find such mutations in around 200
samples analyzed, and identified alternative splicing of exon 14
(leading to truncated IKKa) in only one CRC sample. Thus, we
propose that themain source of p45-IKKa in CRC cells is proteo-
lytic processing of IKKa by cathepsins. This is consistent with
increased cathepsin activity found in CRC that can be associ-
ated with the enhanced aerobic glycolysis, previously described
by Warburg (Swietach et al., 2007), but also with other cancer-
related pathways such as erbB2-K-RAS (Fehrenbacher et al.,
2008; Kim et al., 1998), JAK-STAT (Kreuzaler et al., 2011), or
vitamin D-cystatin (Alvarez-Dı´az et al., 2009). In addition, we
found that mutations in a caspase consensus site of IKKa also
reduced p45-IKKa generation, which might suggest that the
presence of adjacent protease binding sites might facilitate
cathepsin recognition or that the caspase site is functional under
specific conditions. Whether cathepsin-mediated processing is
differentially required to generate cytoplasmic or nuclear p45-
IKKa is somewhat puzzling and requires further investigation.
Most important, in CRC cells cathepsin B and L colocalizedForty-eight hours after transfection cell lysates were immunoprecipitated with
a but not with HA-IKKb.
with HA-FL-IKKa, HA-FL-IKKa plus MT-p45-IKKa, or MT-p45-IKKa alone. The
Ponceau staining of GST proteins is shown. Inputs represent 10%of the lysate.
tected with a-IKKa antibody.
-IKKa, or both constructs. Cytoplasmic, nuclear and chromatin fractions were
aminB, and histone H3 are shown as fractionation and loading controls.
also Figure S4.
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Figure 6. p45-IKKa Promotes Phosphorylation of Specific Substrates Both In Vitro and Vivo
(A) a-IKKa precipitates from fractions 19–25 and 38–45 and western blot analysis to determine the presence of FL or truncated active IKKa.
(B) Kinase activity of the a-IKKa and a-P-IKKa/b precipitates from Superdex200 fractions was assayed on GST-NCoR (amino acids 2256–2452) and detected by
32P incorporation. Total levels of GST-N-CoR protein are shown.
(C) IKKa KOMEFs were transfected with the indicated plasmids and selected for 72 hr with puromycin. Whole-cell extracts or chromatin extracts were obtained
and analyzed bywestern blot with the indicated antibodies. P-SMRT antibody detected different isoforms ranging from 150 to 300 kDa. Levels of a-tubulin, PCNA
and histone H3 are shown as loading controls.
(D) Quantitative real-time PCR showing the expression levels of different SMRT-repressed genes in the IKKa KO MEFs reconstituted as described.
(E) Phosphorylation of SMRT and histone H3 was analyzed by western blot analysis in IKKa-depleted HCT116 cells transduced with the indicated IKKa
constructs. In the a-IKKa blot, the asterisk indicates the p45 fragment generated from FL-IKKa and arrows indicate the unprocessed proteins codified by
exogenous FL-IKKa and p45-IKKa constructs.
(F) Western blot showing the levels of IkBa phosphorylation in cells transduced with the indicated constructs.
(G) Western blot showing phosphorylation of exogenous myc-IKKa (WT and 3M) and IkBa induced by TAK1.
(H) Expression levels of different SMRT-repressed genes in the indicated cell pools as determined by quantitative real-time PCR.
In (D) and (H), statistically significance was determined using t test (*p < 0.05; **p < 0.01, ***p < 0.001). Error bars represent SD. All experiments were performed
a minimum of three times with comparable results. See also Figure S5.
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Figure 7. Generation of p45-IKKa Is Required to Maintain CRC Cell Growth In Vitro and in Vivo
(A) Cells transduced with the indicated shRNAs were seeded at 103 cells per well (in six-well plates) and quantified after 1 week.
(B) Effects of IKKa depletion and reintroduction of the different IKKa constructs in the proliferation ratio of HCT116 and HT-29 cells.
(C and D) Flow cytometry analysis of AnnexinV binding (C) and cell cycle (D) in HCT116 cells transduced with the indicated constructs.
(E) Generation of tumor xenografts fromHCT116 cells expressingWT or the noncleavable IKKa 3Mmutant. Three representative from five animals included in this
experiment are shown.
(F and G) Measurement of tumor size (F) and weight (G) 3 weeks after injection.
Statistical significance was determined using t test (*p < 0.05; **p < 0.01; n.s., no significance). Error bars represent SD. See also Figure S6.with P-IKK in cytoplasmic ring-shape structures, corresponding
to endosomal vesicles that express RAB5, suggesting that IKKa
processing and activation occurs previous to its nuclear translo-Ccation. Similar mechanisms of endosomal-mediated processing
have been shown to regulate ligand-independent activation of
Notch (Wilkin et al., 2008), activation of interferon responseell Reports 2, 840–854, October 25, 2012 ª2012 The Authors 851
through TLR4 (Kagan et al., 2008; Tseng et al., 2010), death
signaling induced by the TNF-a receptor (Schneider-Brachert
et al., 2004), and dorsoventral specification in Drosophila (Lund
et al., 2010).
Interestingly, our results indicate that p45-IKKa is not
restricted to CRC since nonphosphorylated forms are consis-
tently found in the cytoplasm of nontransformedMEF and human
colonic mucosa. However, homozygous mutations of human
IKKa leading to a premature STOP codon at position 422 results
in a lethal syndrome due to severe fetal malformation defects
(Lahtela et al., 2010), indicating the functional requirement of
one FL allele. Further work, including generation of new animal
models should decipher the physiological and pathological
contribution of p45-IKKa. However, we found that cancer cells
lacking IKKa cannot form tumors in vivo when reconstituted
with a noncleavable IKKa mutant.
The relevance of this work resides in the characterization of
p45-IKKa, which function is not directly related with NF-kB but
holds important tumorigenic potential. This finding opens the
possibility of designing new anticancer treatments targeting
IKKa cleavage that should restrict the negative effects of inhibit-
ing general IKK activity and thus NF-kB. In addition, we have
generated an antibody that specifically recognizes p45-IKKa
by IHC, IF, and IP of CRC samples, which in the near future will
be applicable, likely in combination with P-IKK detection, for
analysis of human tumors, stratification of CRC patients, and
other clinical-related applications.EXPERIMENTAL PROCEDURES
Human Colorectal Samples
Samples from patients were obtained from the archives of the Tumor Bank of
Hospital del Mar. All patients gave written consent to donate the tumor
specimen. The ethics committee of our institution approved the study.
Production of Monoclonal Antibodies against p45-IKKa
These antibodies were generated by Abyntek (Spain) using the peptide aa
241–424 of human IKKa as immunogen.
Gel Filtration Assay on Superdex200 Column
HCT116 nuclear extracts (100 ml) were lysed in PBS containing 0.5% Triton
X-100, 1 mM EDTA, 100 mM Na-orthovanadate, 0.25 mM phenylmethanesul-
fonylfluoride (PMSF), and complete protease inhibitor cocktail (Roche, Basel,
Switzerland), centrifuged, and loaded on Superdex200 gel filtration column
(GE Healthcare). One drop (40 ml) per fraction was collected and analyzed by
western blot.
Protein Kinase Assays
Nuclear fractions 19–27 and 36–45 from Superdex200 column were pre-
cleared and incubated with a-IKKa or a-P-IKKa/b overnight at 4C. Precipi-
tates were captured with Protein A-Sepharose, washed and assayed for their
kinase activity on GST fusion proteins. Kinase reaction was performed at 30C
in 20 mM Tris (pH 7.5), 5 mM MgCl2, and 1 mM DTT.
Statistical Methods
Categorical data were compared by use of Fisher’s exact test. A nonpara-
metric analysis of variance was used for the analysis of the ordinal expres-
sion of P-IKK data by applying a rank transformation on the dependent
variable. Analysis was performed using SAS version 9.1.3 software (SAS
Institute Inc., Cary, NC), and level of significance was established at 0.05
(two-sided).852 Cell Reports 2, 840–854, October 25, 2012 ª2012 The AuthorsTumor Xenografts
HCT116 and HT-29 cells were transduced with different IKKa-retroviral
vectors and sorted based on YFP expression. Then, cells were transduced
with shRNA vectors, selected for 3 days with puromycin, and tested for the
expression of the target proteins. Cells (2 3 104) were suspended in matrigel
and injected subcutaneously in nude mice, and, after 3 weeks, visible tumors
were measured and photographed. Animals were kept under pathogen-free
conditions and all procedures approved by the Animal Care Committee.
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